




Figure 3. MerTK/CD206^{neg} and MerTK/CD206^{pos} STM populations have distinct pro- and anti-inflammatory phenotypes respectively. (a) Overview of sorting strategy for MerTK positive and negative STMs (n=47 patients), and functional studies. In vitro production by MerTK positive and negative STMs of (b-c) pro- and anti-inflammatory mediators, and (d) resolvin D1. (e) Expression of MerTK on MerTK/CD206^{pos} STMs are reduced in active RA. (f) UMAP of S100A12 mRNA expression on STM (g) Production of S100A12 by LPS-stimulated MerTK/CD206^{neg} and MerTK/CD206^{pos} STMs FACS-sorted from active RA or remission RA. (h) Soluble mediators differentially expressed in the MerTK^{neg} -CD52^{pos}/S100A12^{pos} cluster between conditions. * p<0.05, adjusted by Bonferroni.